Dosing
VWF:RCo and FVIII content identified and labeled for prescribing precision
With an average VWF:RCo to FVIII ratio of 2.4 to 1, Humate-P successfully achieves
therapeutic levels of VWF without raising FVIII to supranormal levels.1
Dosing overview
Humate-P is labeled in VWF:RCo for dosing accuracy in VWD:
- Treatment of bleeding episodes:
- Administer 40-80 IU VWF:RCo per kg body weight every 8-12 hours
- Prevention of excessive bleeding during and after surgery:
- Surgical dosing differs by type of surgery (ie, major, minor) and should be customized
to patient need according to baseline and target levels of VWF:RCo and FVIII
- In emergency situations, administer 50-60 IU/kg body weight
- Please see Dosage and Administration in the
full Prescribing Information
For added convenience, use the Humate-P
dosing calculator.
A variety of vial sizes
Humate-P is available in a range of vial sizes for convenient dosing, transportation,
and storage.
Important Safety Information
Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.
Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.
Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.
Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.
Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.